Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.
Strykagen has raised $959K in total funding. The most recent round was Grant. The last funding was announced in September 2023.
Strykagen's investors include National Institutes of Health.
Strykagen is headquartered in Reno, United States.
Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.
Strykagen is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Strykagen — Funding & Investors." VCBacked, September 15, 2023, https://www.vcbacked.co/company/strykagen. Accessed August 1, 2026.
VCBacked. (2023). Strykagen — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/strykagen
{{cite web |title=Strykagen — Funding & Investors |url=https://www.vcbacked.co/company/strykagen |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated